These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 35101585)

  • 1. Diagnosis and treatment of therapy-related acute myeloid leukemia.
    Strickland SA; Vey N
    Crit Rev Oncol Hematol; 2022 Mar; 171():103607. PubMed ID: 35101585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CPX-351: changing the landscape of treatment for patients with secondary acute myeloid leukemia.
    Talati C; Lancet JE
    Future Oncol; 2018 May; 14(12):1147-1154. PubMed ID: 29378418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
    Kantarjian HM; Kadia TM; DiNardo CD; Welch MA; Ravandi F
    Cancer; 2021 Apr; 127(8):1186-1207. PubMed ID: 33734442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review.
    Megías-Vericat JE; Martínez-Cuadrón D; Sanz MÁ; Poveda JL; Montesinos P
    Expert Rev Clin Pharmacol; 2019 Mar; 12(3):197-218. PubMed ID: 30672340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges in the diagnosis and treatment of secondary acute myeloid leukemia.
    Ossenkoppele G; Montesinos P
    Crit Rev Oncol Hematol; 2019 Jun; 138():6-13. PubMed ID: 31092386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postremission therapy with repeated courses of high-dose cytarabine, idarubicin, and limited autologous stem cell support achieves a very good long-term outcome in European leukemia net favorable and intermediate-risk acute myeloid leukemia.
    Borlenghi E; Cattaneo C; Cerqui E; Archetti S; Bertoli D; Bellotti D; Gramegna D; Soverini G; Oberti M; Schieppati F; Pagani C; Passi A; Sciumé M; Farina M; Carbone C; Crippa C; Dalceggio D; Tucci A; Rossi G
    Hematol Oncol; 2020 Dec; 38(5):754-762. PubMed ID: 32950042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Significance of Complex Karyotypes in Acute Myeloid Leukemia.
    Daneshbod Y; Kohan L; Taghadosi V; Weinberg OK; Arber DA
    Curr Treat Options Oncol; 2019 Feb; 20(2):15. PubMed ID: 30741367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The leukemia strikes back: a review of pathogenesis and treatment of secondary AML.
    Cheung E; Perissinotti AJ; Bixby DL; Burke PW; Pettit KM; Benitez LL; Brown J; Scappaticci GB; Marini BL
    Ann Hematol; 2019 Mar; 98(3):541-559. PubMed ID: 30666431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CPX-351 daunorubicin-cytarabine liposome: a novel formulation to treat patients with newly diagnosed secondary acute myeloid leukemia.
    Cafaro A; Giannini MB; Silimbani P; Cangini D; Masini C; Ghelli Luserna Di Rorà A; Simonetti G; Martinelli G; Cerchione C
    Minerva Med; 2020 Oct; 111(5):455-466. PubMed ID: 32955826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study.
    Leith CP; Kopecky KJ; Godwin J; McConnell T; Slovak ML; Chen IM; Head DR; Appelbaum FR; Willman CL
    Blood; 1997 May; 89(9):3323-9. PubMed ID: 9129038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach.
    Boddu PC; Kantarjian HM; Ravandi F; Garcia-Manero G; Verstovsek S; Jabbour EJ; Takahashi K; Bhalla K; Konopleva M; DiNardo CD; Ohanian M; Pemmaraju N; Jain N; Pierce S; Wierda WG; Cortes JE; Kadia TM
    Cancer; 2017 Aug; 123(16):3050-3060. PubMed ID: 28387922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment Options.
    Richardson DR; Green SD; Foster MC; Zeidner JF
    Curr Hematol Malig Rep; 2021 Feb; 16(1):97-111. PubMed ID: 33609248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging therapies for AML with myelodysplasia-related changes: slowly but surely moving the needle.
    Phillips DF; Zeidner JF
    Expert Opin Emerg Drugs; 2021 Sep; 26(3):245-257. PubMed ID: 34227451
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect and prognostic analysis of treatment for acute myeloid leukemia using Chinese drugs combined with chemotherapy.
    Hu XM; Liu F; Zheng CM; Li L; Liu C; Zhang SS; Xiao HY; Yang XH; Wang HZ; Xu YG; Hu NP; Ma R
    Chin J Integr Med; 2009 Jun; 15(3):193-7. PubMed ID: 19568712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3+7 Combined Chemotherapy for Acute Myeloid Leukemia: Is It Time to Say Goodbye?
    Tang K; Schuh AC; Yee KW
    Curr Oncol Rep; 2021 Aug; 23(10):120. PubMed ID: 34350512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current and emerging therapies for acute myeloid leukemia.
    Robak T; Wierzbowska A
    Clin Ther; 2009; 31 Pt 2():2349-70. PubMed ID: 20110045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute myeloid leukemia: 2013 update on risk-stratification and management.
    Estey EH
    Am J Hematol; 2013 Apr; 88(4):318-27. PubMed ID: 23526416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML.
    Cortes JE; Lin TL; Uy GL; Ryan RJ; Faderl S; Lancet JE
    J Hematol Oncol; 2021 Jul; 14(1):110. PubMed ID: 34256819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy.
    Jabbour E; Daver N; Champlin R; Mathisen M; Oran B; Ciurea S; Khouri I; Cornelison AM; Ghanem H; Cardenas-Turanzas M; Popat U; Ravandi F; Giralt S; Garcia-Manero G; Cortes J; Kantarjian H; de Lima M
    Am J Hematol; 2014 Apr; 89(4):395-8. PubMed ID: 24375514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic hematopoietic cell transplantation for adult patients with treatment-related acute myeloid leukemia during first remission: Comparable to de novo acute myeloid leukemia.
    Tang FF; Huang XJ; Zhang XH; Chen H; Chen YH; Han W; Chen Y; Wang FR; Wang Y; Wang JZ; Yan CH; Sun YQ; Mo XD; Liu KY; Xu LP
    Leuk Res; 2016 Aug; 47():8-15. PubMed ID: 27239735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.